Cetrorelix
 |
| Systematic (IUPAC) name |
| Acetyl-D-3-(2´-naphtyl)-alanine- D-4-chlorophenylalanine-D-3-(3´-pyridyl)- alanine-L-serine-L-tyrosine-D-citrulline-L- leucine-L-arginine-L-proline-D- alanine-amide |
| Clinical data |
| AHFS/Drugs.com |
Micromedex Detailed Consumer Information |
| Pregnancy cat. |
X (US) |
| Legal status |
℞-only (US) |
| Routes |
Subcutaneous injection |
| Pharmacokinetic data |
| Bioavailability |
85% |
| Protein binding |
86% |
| Half-life |
62.8 hours / 3mg single dose; 5 hours / 0.25 mg single dose; 20.6 hours / 0.25mg multiple doses |
| Excretion |
feces (5% to 10% as unchanged drug and metabolites); urine (2% to 4% as unchanged drug) |
| Identifiers |
| CAS number |
120287-85-6  Y |
| ATC code |
H01CC02 |
| PubChem |
CID 16130924 |
| DrugBank |
DB00050 |
| ChemSpider |
10482082 Y |
| UNII |
OON1HFZ4BA Y |
| KEGG |
D07665 Y |
| ChEBI |
CHEBI:59224 Y |
| ChEMBL |
CHEMBL1200490  N |
| Chemical data |
| Formula |
C70H92ClN17O14 |
| Mol. mass |
1431.06 g/mol |
-
InChI=1S/C70H92ClN17O14/c1-39(2)31-52(61(94)82-51(15-9-28-77-69(73)74)68(101)88-30-10-16-58(88)67(100)79-40(3)59(72)92)83-60(93)50(14-8-29-78-70(75)102)81-63(96)54(34-43-20-25-49(91)26-21-43)86-66(99)57(38-89)87-65(98)56(36-45-11-7-27-76-37-45)85-64(97)55(33-42-18-23-48(71)24-19-42)84-62(95)53(80-41(4)90)35-44-17-22-46-12-5-6-13-47(46)32-44/h5-7,11-13,17-27,32,37,39-40,50-58,89,91H,8-10,14-16,28-31,33-36,38H2,1-4H3,(H2,72,92)(H,79,100)(H,80,90)(H,81,96)(H,82,94)(H,83,93)(H,84,95)(H,85,97)(H,86,99)(H,87,98)(H4,73,74,77)(H3,75,78,102)/t40-,50-,51+,52+,53-,54+,55-,56-,57+,58+/m1/s1 Y
Key:SBNPWPIBESPSIF-MHWMIDJBSA-N Y
|
 N (what is this?) (verify)
|
Cetrorelix acetate is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). A synthetic decapeptide, it is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, cetrorelix is used in assisted reproduction to inhibit premature luteinizing hormone surges. The drug works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of LH and FSH. It is administered as either multiple 0.25 mg daily subcutaneous injections or as a single-dose 3 mg subcutaneous injection. The duration of the 3 mg single dose is four days; if hCG is not administered within four days, a daily 0.25 mg dose is started and continued until hCG is administered.
[edit] Use in IVF
Cetrorelix is marketed by Merck Serono as Cetrotide for use in in-vitro fertilization in all countries except Japan, where it is marketed by Shionogi and Nippon Kayaku.[1] Aeterna Zentaris receives royalties on these sales and retains rights to develop cetrorelix for other indications. In IVF use it is injected daily after follicle stimulation has been initiated and evidence of follicle maturation is approaching; given daily it prevents an endogenous LH surge that would trigger an untimely ovulation prior to the hCG administration by the treating physician. As an alternative to the GNRH antagonist, also a GNRH agonist could be given, but agonist have to be started earlier to overcome the agonistic effect. Cetrorelix can be mixed with follitropin alpha without compromising their reported safety and efficacy.[2]
[edit] Implications
Over a period of 3 weeks, daily injections of Cetrorelix were administered to 12 men in order to suppress testosterone levels. Testosterone levels were significantly suppressed as compared to a control group. During this time of suppression, increases in High Density Lipoproteins (HDL's) were seen. HDL's are responsible for removing cholesterol from the blood and higher amounts are correlated with increased cardivascular health. (von Eckardstein, 1997)
[edit] Contraindications
The use of Cetrorelix is contraindicated in severe renal impairment. It is not intended for women aged 65 years or older. Use in women with severe allergic conditions is not recommended. Use with caution in women with active allergies or history of allergies.
[edit] References
von Eckardstein, A. “Suppression of Endogenous Testosterone in Young Men Increases Serum Levels of High Density Lipoprotein Subclass Lipoprotein A-I and Lipoprotein(a).” Journal of Clinical Endocrinology, v. 82 issue 10, 1997, p. 3367.
(what is this?) (verify)
